| 09:44a | SONA NANOTECH : IIROC Trading Halt - SONA | AQ |
| 09:43a | Wall St. dips amid U.S. protests, China tensions | RE |
| 09:43a | 18 Squared and CapZone Announce Opportunity Zone Investment | BU |
| 09:43a | STRATEGY ANALYTICS : Ultrawideband Chips on the Threshold of Success | BU |
| 09:42a | Facebook, Snapchat join chorus of companies condemning George Floyd death, racism | RE |
| 09:42a | FIRST UNITED CORP/MD/ : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 09:42a | ELLIE MAE : Virtual Experience 2020 Sees Successful Conclusion | AQ |
| 09:41a | DAIICHI SANKYO : AstraZeneca - Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial | AQ |
| 09:41a | BRIDGEBIO PHARMA : QED Therapeutics Presents Data on Infigratinib In Cholangiocarcinoma and Urothelial Carcinoma | AQ |
| 09:41a | DAIICHI SANKYO : AstraZeneca and Daiichi Sankyo Company, Limited - Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer | AQ |
| 09:41a | NOVARTIS : announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar + Mekinist following surgery | AQ |
| 09:41a | ALLOGENE THERAPEUTICS : With collaborator servier, reports positive results from its phase 1 alpha study of allo-501 in relapsed/refractory non-hodgkin lymphoma | AQ |
| 09:41a | AUTOLUS THERAPEUTICS : presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program | AQ |
| 09:41a | HARPOON THERAPEUTICS : Presents interim phase 1 data from an ongoing dose escalation trial for the psma-targeting tritac hpn424 at the asco20 virtual scientific program | AQ |
| 09:41a | GENOCEA BIOSCIENCES : Presents updated long-term safety, immunogenicity and durability data from gen-009 neoantigen vaccine phase 1/2a trial part a at virtual asco 2020 | AQ |
| 09:41a | NGM BIOPHARMACEUTICALS : Bio to Present at Two Upcoming Investor Conferences | AQ |
| 09:41a | Oncolytics Biotech Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting | AQ |
| 09:41a | CHUGAI PHARMACEUTICAL : Updated Data of Overall Survival and Safety from the ALEX Study for Chugai's Alecensa Presented at the 2020 American Society of Clinical Oncology | AQ |
| 09:41a | REGENERON PHARMACEUTICALS : - libtayo longer-term results in advanced cutaneous squamous cell carcinoma presented at asco 2020 show durable responses that deepen over time | AQ |
| 09:41a | DAIICHI SANKYO : AstraZeneca - Enhertu demonstrated meaningful clinical activity in patients with HER2-mutant non-small cell lung cancer in interim analysis of Phase II DESTINY-Lung01 trial | AQ |
| 09:41a | SUN PHARMACEUTICAL INDUSTRIES : Pharma receives approval from DCGI to initiate clinical trial with Nafamostat in Covid-19 patients | AQ |
| 09:41a | PFIZER : Provides update on phase 3 pallas trial of ibrance plus endocrine therapy in hr+, her2- early breast cancer | AQ |
| 09:41a | NOVO NORDISK A/S : Basilea announces appointment of new Head of Global Quality Management | AQ |
| 09:41a | Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules against Sawai and Nichi-Iko | AQ |
| 09:41a | REGENERON PHARMACEUTICALS : Completes secondary offering of common stock held by sanofi | AQ |
| 09:41a | CHUGAI PHARMACEUTICAL : Obtains Approval for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Novartis' MET inhibitor, Capmatinib | AQ |
| 09:41a | Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program | AQ |
| 09:41a | MYOVANT SCIENCES : Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer | AQ |
| 09:41a | KALYTERA THERAPEUTICS : Announces Data Demonstrating that R-107 Preserves Organ Function in a Murine Study Mimicking COVID-19 Lung Disease | AQ |
| 09:41a | SUMITOMO DAINIPPON PHARMA : Announces Merger of US consolidated subsidiaries | AQ |
| 09:41a | Chugai and FRONTEO Enter into a License Agreement for AI-based Drug Discovery Support System | AQ |
| 09:41a | LIGAND PHARMACEUTICALS INCORPORATED : Announces icagen's expansion of collaboration with roche to develop and commercialize therapies for neurological diseases | AQ |
| 09:41a | GLYCOMIMETICS : to Present at Upcoming Jefferies Virtual Healthcare Conference | AQ |
| 09:41a | AMNEAL PHARMACEUTICALS : LLC Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended Release Tablets, USP, 500 mg and 750 mg | AQ |
| 09:41a | CARDIOL THERAPEUTICS TO WEBCAST VIRTUAL ANNUAL GENERAL MEETING ON JUNE 1ST AT 4 : 30 p.m. EDT | AQ |
| 09:41a | Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting | AQ |
| 09:41a | XSPRAY PHARMA PUBL : initiates pivotal registration studies with HyNap-Dasa for the market approval application in the United States | AQ |
| 09:41a | ABBVIE : FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women | AQ |
| 09:41a | INITIATOR PHARMA A/S : - Publication of memorandum | AQ |
| 09:41a | ASTRAZENECA : Imfinzi plus tremelimumab demonstrated promising clinical activity and tolerability in patients with advanced liver cancer | AQ |
| 09:41a | SYROS PHARMACEUTICALS : Presents New Preclinical Data on SY-5609 at 2020 ASCO Virtual Scientific Program | AQ |
| 09:41a | INTELLIPHARMACEUTICS INTERNATIONAL : Announces First Quarter 2020 Results | AQ |
| 09:41a | MARKER THERAPEUTICS : Reports interim results of its multitaa-specific t cell therapy in patients with pancreatic adenocarcinoma | AQ |
| 09:41a | ASTRAZENECA : Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial | AQ |
| 09:41a | MODERNA : Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine against Novel Coronavirus | AQ |
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
